Literature DB >> 15947238

Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice.

Vladimir R Babaev1, Patricia G Yancey, Sergey V Ryzhov, Valentina Kon, Matthew D Breyer, Mark A Magnuson, Sergio Fazio, MacRae F Linton.   

Abstract

OBJECTIVE: Peroxisome proliferator-activated receptor gamma (PPARgamma) is highly expressed in macrophage-derived foam cells of atherosclerotic lesions, and its expression may have a dramatic impact on atherosclerosis. METHODS AND
RESULTS: To investigate the contribution of macrophage PPARgamma expression on atherogenesis in vivo, we generated macrophage-specific PPARgamma knockout (MacPPARgammaKO) mice. C57BL/6 and low-density lipoprotein (LDL) receptor-deficient (LDLR(-/-)) mice were reconstituted with MacPPARgammaKO or wild-type marrow and challenged with an atherogenic diet. No differences were found in serum lipids between recipients reconstituted with MacPPARgammaKO and wild-type marrow. In contrast, both C57BL/6 and LDLR(-/-) mice transplanted with MacPPARgammaKO marrow had significantly larger atherosclerotic lesions than control recipients. In addition, MacPPARgammaKO-->LDLR(-/-) mice had higher numbers of macrophages in atherosclerotic lesions compared with controls. Peritoneal macrophages isolated from the MacPPARgammaKO mice had decreased uptake of oxidized but not acetylated LDL and showed no changes in either cholesterol efflux or inflammatory cytokine expression. Macrophages from MacPPARgammaKO mice had increased levels of migration and CC chemokine receptor 2 (CCR2) expression compared with wild-type macrophages.
CONCLUSIONS: Thus, macrophage PPARgamma deficiency increases atherosclerosis under conditions of mild and severe hypercholesterolemia, indicating an antiatherogenic role for PPARgamma, which may be caused, at least in part, by modulation of CCR2 expression and monocyte recruitment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15947238     DOI: 10.1161/01.ATV.0000173413.31789.1a

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  87 in total

Review 1.  Control of macrophage activation and function by PPARs.

Authors:  Ajay Chawla
Journal:  Circ Res       Date:  2010-05-28       Impact factor: 17.367

2.  Pro- and antiatherogenic effects of a dominant-negative P465L mutation of peroxisome proliferator-activated receptor-γ in apolipoprotein E-Null mice.

Authors:  Avani A Pendse; Lance A Johnson; Hyung-Suk Kim; Marcus McNair; C Taylor Nipp; Carolyn Wilhelm; Nobuyo Maeda
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-04-26       Impact factor: 8.311

3.  Cyclooxygenase products and atherosclerosis.

Authors:  Macrae F Linton; Sergio Fazio
Journal:  Drug Discov Today Ther Strateg       Date:  2008

4.  Inhibition of Macrophage CD36 Expression and Cellular Oxidized Low Density Lipoprotein (oxLDL) Accumulation by Tamoxifen: A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR)γ-DEPENDENT MECHANISM.

Authors:  Miao Yu; Meixiu Jiang; Yuanli Chen; Shuang Zhang; Wenwen Zhang; Xiaoxiao Yang; Xiaoju Li; Yan Li; Shengzhong Duan; Jihong Han; Yajun Duan
Journal:  J Biol Chem       Date:  2016-06-29       Impact factor: 5.157

5.  Protective Role of Peroxisome Proliferator-Activated Receptor-γ in the Development of Intracranial Aneurysm Rupture.

Authors:  Kenji Shimada; Hajime Furukawa; Kosuke Wada; Masaaki Korai; Yuan Wei; Yoshiteru Tada; Atsushi Kuwabara; Fumiaki Shikata; Keiko T Kitazato; Shinji Nagahiro; Michael T Lawton; Tomoki Hashimoto
Journal:  Stroke       Date:  2015-04-30       Impact factor: 7.914

6.  Disruption of endothelial peroxisome proliferator-activated receptor γ accelerates diet-induced atherogenesis in LDL receptor-null mice.

Authors:  Aijuan Qu; Yatrik M Shah; Soumen K Manna; Frank J Gonzalez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-10-20       Impact factor: 8.311

Review 7.  PPARgamma in human and mouse physiology.

Authors:  Sami Heikkinen; Johan Auwerx; Carmen A Argmann
Journal:  Biochim Biophys Acta       Date:  2007-03-27

8.  Peroxisome proliferator-activated receptor-gamma regulates the expression of alveolar macrophage macrophage colony-stimulating factor.

Authors:  Tracey L Bonfield; Mary Jane Thomassen; Carol F Farver; Susamma Abraham; Mary T Koloze; Xia Zhang; David M Mosser; Daniel A Culver
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

9.  PPARγ Deficiency Suppresses the Release of IL-1β and IL-1α in Macrophages via a Type 1 IFN-Dependent Mechanism.

Authors:  Kassandra J Weber; Madeline Sauer; Li He; Eric Tycksen; Gowri Kalugotla; Babak Razani; Joel D Schilling
Journal:  J Immunol       Date:  2018-08-24       Impact factor: 5.422

Review 10.  Macrophage immunomodulation in chronic osteolytic diseases-the case of periodontitis.

Authors:  Corneliu Sima; Ana Viniegra; Michael Glogauer
Journal:  J Leukoc Biol       Date:  2018-11-19       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.